Beyond platelet activation: dysregulated lipid metabolism in defining risk and pathophysiology of VITT.

ABSTRACT:

Background

VITT has emerged as a rare but serious adverse event linked primarily to adenoviral vector COVID-19 vaccinations, such as ChAdOx1-S (Oxford/AstraZeneca) vaccination. The syndrome is characterized by thrombosis with thrombocytopenia, elevated D-dimer, and pathologic platelet factor 4 antibodies within 42 days of vaccination.

Objectives

Despite dysregulated lipid metabolism underpinning many thrombotic conditions, the role of lipid alterations in VITT remains unexplored. Here, we examined the plasma lipidome of patients with VITT and compared it with those following ChAdOx1-S vaccination and with unprovoked venous thromboembolism (VTE) to understand the role of lipids in VITT pathophysiology.

Methods

This was a multicenter, prospective cohort study evaluating

SUBMITTER: Stevens H 

PROVIDER: S-EPMC11879676 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature